SMIN

2,536

+0.67%↑

SMIN

2,536

+0.67%↑

SMIN

2,536

+0.67%↑

SMIN

2,536

+0.67%↑

SMIN

2,536

+0.67%↑

Search

Syncona Ltd

Abierto

87 0.23

Resumen

Variación precio

24h

Actual

Mínimo

85.2

Máximo

87

Métricas clave

By Trading Economics

Ingresos

-25M

Ventas

20M

Margen de beneficios

-127.345

Empleados

1,215

EBITDA

-25M

Dividendos

By Dow Jones

Próximas Ganancias

18 jun 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

536M

Apertura anterior

86.77

Cierre anterior

87

Syncona Ltd Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

29 abr 2026, 23:53 UTC

Ganancias

Naver Posts Weaker First-Quarter Earnings

29 abr 2026, 23:41 UTC

Acciones populares

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 abr 2026, 23:55 UTC

Ganancias

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 abr 2026, 23:54 UTC

Ganancias

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 abr 2026, 23:52 UTC

Ganancias

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 abr 2026, 23:51 UTC

Ganancias

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 abr 2026, 23:51 UTC

Charlas de Mercado

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 abr 2026, 23:34 UTC

Charlas de Mercado

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 abr 2026, 23:24 UTC

Ganancias

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 abr 2026, 23:24 UTC

Ganancias

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 abr 2026, 23:24 UTC

Ganancias

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 abr 2026, 23:24 UTC

Ganancias

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 abr 2026, 23:22 UTC

Ganancias

China Longyuan 1Q Net CNY1.70B, Down 14%

29 abr 2026, 23:22 UTC

Ganancias

China Longyuan: Power Generation Down 2.9% as of End-March

29 abr 2026, 23:20 UTC

Ganancias

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 abr 2026, 23:20 UTC

Ganancias

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 abr 2026, 23:19 UTC

Ganancias

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 abr 2026, 23:19 UTC

Ganancias

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 abr 2026, 23:19 UTC

Ganancias

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 abr 2026, 23:19 UTC

Ganancias

China Vanke 1Q Loss Narrows>000002.SZ

29 abr 2026, 23:18 UTC

Ganancias

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 abr 2026, 23:17 UTC

Ganancias

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 abr 2026, 23:15 UTC

Ganancias

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 abr 2026, 23:15 UTC

Ganancias

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 abr 2026, 23:13 UTC

Ganancias

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 abr 2026, 23:12 UTC

Ganancias

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 abr 2026, 23:11 UTC

Ganancias

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 abr 2026, 23:11 UTC

Ganancias

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 abr 2026, 23:04 UTC

Ganancias

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 abr 2026, 23:04 UTC

Ganancias

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Comparación entre iguales

Cambio de precio

Syncona Ltd previsión

Consenso

By TipRanks

0 ratings

0

Comprar

0

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

EBITDA

Beneficio operativo

$

Acerca de Syncona Ltd

Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules. The fund invests in the public equity and fixed income markets across the globe. It targets attractive medium to long term returns by investing in leading long-only and alternative investment funds with proven managers and across multiple asset classes. The firm invests in separately managed account portfolios.
help-icon Live chat